Sweta Patel, DO
Obstetrics & Gynecology · Silver Spring, MDNPI 1033435714
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations.
Across 134 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$596
- Exeltis, USA Inc.$412
- Therapeuticsmd, Inc.$179
- Astellas Pharma US Inc$163
- Daiichi Sankyo Inc.$119
- Mayne Pharma Commercial LLC$106
- plus $1K from 23 others
Across 9 payments — averaging $2382.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ferring International Pharmascience Center US$14K
- Bayer$4K
- Myovant Sciences Inc.$3K
What the payments were for
- Food & beverage$2,61299%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $596 |
| Exeltis, USA Inc. | 21 | $412 |
| Therapeuticsmd, Inc. | 7 | $179 |
| Astellas Pharma US Inc | 6 | $163 |
| Daiichi Sankyo Inc. | 6 | $119 |
| Mayne Pharma Commercial LLC | 4 | $106 |
| Amgen | 6 | $105 |
| Pfizer | 7 | $102 |
| Corcept Therapeutics | 1 | $89 |
| Sage Therapeutics, LLC | 5 | $83 |
| Renovia Inc | 1 | $73 |
| Merck | 4 | $71 |
| Bayer | 3 | $70 |
| Medtronic | 1 | $64 |
| Coopersurgical, Inc. | 4 | $58 |
| Organon | 3 | $47 |
| Avion Pharmaceuticals | 3 | $41 |
| Hologic Sales And Service, LLC | 2 | $34 |
| Scynexis, Inc. | 2 | $32 |
| Mylan Pharmaceuticals Inc. | 2 | $28 |
| AMAG Pharmaceuticals, Inc. | 2 | $26 |
| Roche Diagnostics Corporation | 1 | $24 |
| Millicent US Inc | 1 | $23 |
| Biogen | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Myovant Sciences Inc. | 1 | $14 |
| Minerva Surgical, Inc | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
How this compares
$2,637 in reported general payments places this provider in the 80th percentile of 842 obstetrics & gynecology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 11 | $897 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Silver Spring
- Otis StittSilver Spring$641K
- Ifeyinwa StittSilver Spring$19K
- Darryn BandSilver Spring$8K
- Tamara CoatesSilver Spring$6K
- Ashleigh BouchelionSilver Spring$6K
- Anne ShroutSilver Spring$6K
- Randolph LizardoSilver Spring$5K
- Mary SineSilver Spring$5K
- Danielle ShillerBaltimore$221K
- Matthew ReevesChevy Chase$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.